Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry

• Published in: Advances in clinical and experimental medicine : official organ Wroclaw Medical University Vol. 25; no. 4; pp. 633 - 641
• Main Authors: Waszczuk-Gajda, Anna, Mądry, Krzysztof, Machowicz, Rafał, Drozd-Sokołowska, Joanna, Stella-Hołowiecka, Beata, Mital, Andrzej, Obara, Agata, Szmigielska-Kapłon, Anna, Sikorska, Anna, Subocz, Edyta, Jędrzejczak, Wiesław W, Dwilewicz-Trojaczek, Jadwiga
• Format: Journal Article
• Language: English
• Published: Poland 01.07.2016
• Subjects: Aged; Aged, 80 and over; Erythrocyte Transfusion - adverse effects; Female; Ferritins - blood; Humans; Iron Overload - complications; Male; Middle Aged; Myelodysplastic Syndromes - complications; Myelodysplastic Syndromes - mortality; Myelodysplastic Syndromes - therapy; Poland; Proportional Hazards Models; Registries; Retrospective Studies; Survival Analysis; transformation to acute myeloid leukemia; serum ferritin concentration; myelodysplastic syndrome; red blood cell transfusion dependence; hyperferritinemia
• ISSN: 1899-5276
• DOI: 10.17219/acem/62397

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal stem cell disorders characterized by ineffective hematopoiesis, cytopenias and a risk of progression to acute myeloid leukemia (AML). Anemia is the most frequent cytopenia diagnosed in patients with MDS. Regular RBC transfusions are the only treatment option for about 40% of patients. Transfusion-dependent patients develop secondary iron overload. The influence of serum ferritin (SF) concentration on survival and acute myeloid leukemia transformation in MDS patients remains controversial. The data for the Central European population is scarce and so far there is no description for Poland. The aim of this study was to perform a retrospective analysis of the relationship of SF concentration with red blood cell transfusion dependency, survival and transformation to acute myeloid leukemia. We retrospectively evaluated the data of the 819 MDS patients (58% male; median age 70 years) included in the MDS Registry of the MDS Section of the Polish Adult Leukemia Group (PALG). Analyses were performed on 190 patients diagnosed with MDS, maximal 6 months before inclusion to the registry in order to avoid selection bias (a shorter survival of higher risk MDS patients). Patients with hyperferritinemia higher than 1000 ng/L vs. patients with SF concentration lower than 1000 ng/L had a median survival of 320 days vs. 568 days, respectively (p log-rank = 0.014). The following factors were found to significantly worsen survival: RBC-transfusion dependence (p = 0.0033; HR 2.67L), platelet transfusion dependence (p = 0.0071; HR 3.321), hemoglobin concentration lower than 10 g/dL (p = 0.0036; HR 2.97), SF concentration higher than 1000 ng/L (p = 0.0023; HR = 2.94), platelet count lower than 10 G/L (p = 0.0081 HR = 5.04), acute leukemia transformation (p = 0.0081; HR 1.968). Taking into account the relatively low number of patients in previous studies exploring hyperferritinemia in MDS, the results of the first Polish MDS Registry provide important insights. Hyperferritinemia higher than 1000 ng/L can be an important indicator of poor prognosis in MDS.